

31026/39/2020-Policy/Scheme (Pt.2)
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals

Shastri Bhawan, New Delhi
Dated: 25th September, 2024

CORRIGENDUM/ADDENDUM

Subject: - Modification in the guidelines of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country (PLI scheme for Bulk Drugs), relating to definition of Successor-in-interest — reg.

Department of Pharmaceuticals issued Notification guidelines of the PLI Scheme Bulk Drugs on 18.07.2020, which were revised on 29.10.2020, 26.07.2022 and 12.03.2024.

2. Based on the decision taken in the Empowered Committee (EC)) meeting held on 19.08.2024, following amendment in the PLI scheme for Bulk Drugs guidelines of 29.10.2020 are hereby notified:

Clause No.	Existing Clause in the Guidelines	Revised Clause in the Guidelines
2.30	Successor-in-interest: Successor-in-Interest shall mean the new or re-organized entity formed after the merger, de-merger, acquisition, transfer of business or significant change in ownership of an applicant..	Successor-in-interest: Successor-in-Interest shall mean the new or the re-organized entity formed after merger, de-merger, acquisition or transfer of business to any other entity including a wholly owned subsidiary or a significant change in ownership of an applicant.

3. All other clauses in the PLI scheme for Bulk Drugs guidelines dated 29.10.2020 and 26.07.2022 and 12.03.2024 remain the same.

4. This issues with the approval of the competent authority.


(Uma Magesh)

Under Secretary to the Government of India

Tel: 23383392

Email: uma.magesh@nic.in

To,

- Director, NIC, DoP - with a request to upload the same in the DoP website
- Shri Varun Mahajan, IFCI Limited — for further necessary action.